Home > Publications Database > Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals. > print

001     270674
005     20240808164333.0
024 7 _ |a 10.3233/JAD-231335
|2 doi
024 7 _ |a pmid:38848176
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a altmetric:164555868
|2 altmetric
037 _ _ |a DZNE-2024-00846
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sannemann, Lena
|b 0
245 _ _ |a Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
260 _ _ |a Amsterdam
|c 2024
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721814563_7926
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aβ42/ptau181 ratio compared to those with neither SCD nor OBJ.The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnosis
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: psychology
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Cluster Analysis
|2 MeSH
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Alzheimer’s disease continuum
|2 Other
650 _ 7 |a NIA-AA stage 2
|2 Other
650 _ 7 |a amyloid
|2 Other
650 _ 7 |a cerebrospinal fluid biomarkers
|2 Other
650 _ 7 |a neuropsychiatric symptoms
|2 Other
650 _ 7 |a preclinical Alzheimer’s disease
|2 Other
650 _ 7 |a subjective cognitive decline
|2 Other
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 7 |a amyloid beta-protein (1-42)
|2 NLM Chemicals
650 _ 7 |a Alzheimer’s disease continuum
|2 Other
650 _ 7 |a preclinical Alzheimer’s disease
|2 Other
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Bartels, Claudia
|b 1
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 2
|u dzne
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 3
|u dzne
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 4
|u dzne
700 1 _ |a Freiesleben, Silka Dawn
|0 P:(DE-2719)2812392
|b 5
|u dzne
700 1 _ |a Frommann, Ingo
|0 P:(DE-2719)2810481
|b 6
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 7
|u dzne
700 1 _ |a Heneka, Michael
|0 P:(DE-2719)2000008
|b 8
|u dzne
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 9
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 10
|u dzne
700 1 _ |a Kleineidam, Luca
|0 P:(DE-2719)2812139
|b 11
|u dzne
700 1 _ |a Lammerding, Dominik
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 13
|u dzne
700 1 _ |a Munk, Matthias H J
|0 P:(DE-2719)9001516
|b 14
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 15
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 16
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 17
|u dzne
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 18
|u dzne
700 1 _ |a Rostamzadeh, Ayda
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Roy-Kluth, Nina
|0 P:(DE-2719)2812341
|b 20
|u dzne
700 1 _ |a Schild, Ann-Katrin
|0 P:(DE-2719)9001495
|b 21
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 22
|u dzne
700 1 _ |a Schneider, Luisa-Sophie
|0 P:(DE-2719)9002878
|b 23
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 24
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 25
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 26
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 27
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 28
|u dzne
700 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 29
|u dzne
700 1 _ |a Duezel, Emrah
|0 P:(DE-2719)2000005
|b 30
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 31
|e Last author
|u dzne
700 1 _ |a Group, DELCODE Study
|0 P:(DE-HGF)0
|b 32
|e Collaboration Author
773 _ _ |a 10.3233/JAD-231335
|g Vol. 100, no. 1, p. 193 - 205
|0 PERI:(DE-600)2070772-1
|n 1
|p 193 - 205
|t Journal of Alzheimer's disease
|v 100
|y 2024
|x 1387-2877
856 4 _ |u https://pub.dzne.de/record/270674/files/DZNE-2024-00846_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/270674/files/DZNE-2024-00846_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:270674
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2812392
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810481
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811614
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)2000008
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)9002557
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2812139
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9001516
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2811024
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811122
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2812341
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2812035
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)9002878
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2810544
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2000032
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-25
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 0
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka
|l Neuroinflammation, Biomarker
|x 1
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 2
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn ; Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 3
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 4
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 5
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 6
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 7
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 8
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 9
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 10
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 11
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 12
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21